Please login to the form below

Not currently logged in

RedHill Biopharma’s SK2 inhibitor shows promise against coronavirus

Opaganib demonstrate potent inhibition of SARS-CoV-2 in an in vitro test

RedHill Biopharma has announced that its experimental sphingosine kinase-2 (SK2) opaganib demonstrated potent inhibition of SARS-CoV-2 in an in vitro clinical test.

According to the company, the potential first-in-class treatment was able to achieve complete blockage of viral replication in an in vitro model of human lung bronchial tissues.

Opaganib possesses both anti-inflammatory and anti-viral activity, by targeting a host cell component unaffected by viral mutation, which minimises the likelihood of resistance.

RedHill is currently evaluating the SK2 inhibitor in global phase 2/3 and US phase 2 clinical studies for the treatment of severe COVID-19-associated pneumonia.

According to the company, opaganib demonstrated the most potent activity against SARS-CoV-2 compared to all compounds tested in the same study, including the positive control, Gilead’s remdesivir.

“Opaganib’s previously demonstrated anti-inflammatory activity, combined with our now proven specific anti-SARS-CoV-2 viral activity, provides a unique dual mechanism of action with the potential to greatly benefit COVID-19 patients by inhibiting the key drivers of disease progression - viral replication and lung inflammation,” said Mark Levitt, medical director at RedHill.

“This compelling data, using a physiologically relevant human respiratory tissue model, demonstrates opaganib’s potential to strongly inhibit SARS-CoV-2 viral replication, validating the hypotheses underlying our ongoing global phase 2/3 and US phase 2 clinical studies and further supporting their rationale,” he added.

Article by
Lucy Parsons

9th September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....